ANN ARBOR, Mich., July 17 /PRNewswire/ -- NanoBio(R) Corporation, a biopharmaceutical company developing novel anti-infectives and mucosal vaccines to treat and prevent serious infections, today announced that Jerald C. Sadoff, MD, has joined the NanoBio Scientific Advisory Board. Sadoff will assist NanoBio in developing and commercializing its novel vaccines for hepatitis B, influenza and other debilitating conditions. The company’s patented NanoStat technology serves as a delivery system for its mucosal vaccine candidates, while simultaneously adjuvanting and thermally stabilizing the associated antigen.
“Dr. Sadoff brings with him three decades of extensive experience developing vaccines for dozens of diseases, from chicken pox to malaria,” said James Baker, M.D., NanoBio’s chief science officer and founder. “His vast experience will be particularly valuable as NanoBio advances its hepatitis B and influenza vaccines into Phase I studies, and pursues other vaccine candidates based on our technology platform.”
Sadoff joins NanoBio from Aeras Global TB Vaccine Foundation, where he has served as president and chief executive officer since 2003. Dr. Sadoff came to Aeras from Merck, where he was the Executive Director of Clinical Development of Vaccines. While at Merck, Dr. Sadoff led the efforts to develop and obtain licensure for eight vaccines. Before joining Merck, Dr. Sadoff was Director, Division of Communicable Diseases and Immunology, at the Walter Reed Army Institute of Research, where he worked on vaccines against bacterial, viral and parasitic diseases.
Dr. Sadoff serves on the NIAID AIDS Vaccine Research Working Group and the Scientific Advisory Board of the International AIDS Vaccine Initiative. He received his BA and MD from the University of Minnesota at Minneapolis.
About NanoBio
NanoBio(R) Corporation is a privately-held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), methicillin resistant Staphylococcus aureus (MRSA) and mucosal vaccines for influenza and hepatitis B. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.
NanoBio(R) Corporation
CONTACT: John Coffey, Vice President, Business Development of NanoBio(R)Corporation, +1-734-302-9107, john.coffey@nanobio.com
